Pharmaceuticals

A Boston biotech says its new AI platform moves beyond correlation to find the true biological causes of disease, promising a new era for medicine.

With a massively oversubscribed €600M hybrid note offering, plant-based leader Roquette secures major funding and a huge vote of investor confidence.

A novel immunotherapy tames a potent but toxic cancer-fighting agent by locking it inside tumors, offering new hope for patients with resistant cancers.

A new AI platform is revolutionizing how pharma creates complex scientific videos, earning industry award recognition for its speed, savings, and compliance.

A new oral therapy shows a 76% response rate in a hard-to-treat lung cancer, offering a powerful new first-line option for patients with this rare disease.

Biopharma leader Dr. Gavin Barnard joins ATUM as CSO, aiming to leverage AI and advanced tech to fast-track complex therapies from the lab to the clinic.

With founder Frédéric Mascha as Executive Chairman and new CEO Renaud Sermondade, Juvisé Pharmaceuticals is poised for major M&A-fueled global expansion.

Inventia Life Science's new RASTRUM Validated Solutions offer standardized 3D models to tackle the reproducibility crisis in pharmaceutical R&D.

A Chinese biotech has won a key approval for a novel antibody designed to fight deadly leukemias with enhanced safety, marking a new frontier in cancer care.

A new partnership integrates expert rater training with eCOA tech, aiming to reduce costly data errors and accelerate development of new neurological drugs.

With key advisory appointments, NeuraClick aims to overcome long-standing hurdles in peptide drug development for complex brain and metabolic disorders.

With 62 profitable quarters and a major new acquisition, BioSyent prepares to pitch its proven growth strategy to top healthcare investors in Toronto.

A new biotech player is advancing a first-in-class cancer drug that combines two payloads to fight tumors that have become resistant to current therapies.

Backed by Bain Capital and a veteran team, the new biotech has a de-risked pipeline from Bristol Myers Squibb aimed at transforming care for lupus and more.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

A parent-led company gains a U.S. patent for a diazoxide formulation, offering new hope for managing behavioral symptoms in Prader-Willi syndrome.

A new FDA-approved powder form of a common blood pressure drug aims to solve a daily struggle for the elderly, children, and tube-fed patients.

Philip Morris International's upcoming Q1 2026 earnings will be a crucial test of its pivot from cigarettes, with all eyes on ZYN's growth and regulatory hurdles.

A new strategic deal for the Lasix ONYU device aims to secure its key ingredient, transforming heart failure care from the hospital to the living room.